METHOD OF USING PROTEIN KINASE A ACTIVATOR AND INHIBITOR IN PREPARATION OF DRUGS FOR TREATING DISEASES ASSOCIATED WITH CHANGES IN PLATELET COUNTS AND FOR INHIBITING AND PROMOTING PLATELET APOPTOSIS
A method of using protein kinase A (PKA) activator and inhibitor in preparations of drugs for treating diseases associated with changes in platelet counts. Protein kinase A regulates platelet apoptosis by means of regulating the phosphorylation of serine at BAD position 155； the activation of protein kinase A activity may inhibit the occurrence of endogenous platelet apoptosis, and may also increase circulating platelet counts in experimental animals； in addition, inhibiting PKA activity may induce platelet apoptosis in vitro, while also reducing circulating platelet counts in the body, indicating that PKA inhibitors may participate in the treatment of thrombocytosis, and reduce platelet counts in peripheral circulating blood.
